Daewoong Pharmaceutical has voluntarily withdrawn its application for Nabota's 100-unit product approval in China, aiming to resubmit with expanded dosage options to meet regulatory and market demands.
#YonhapInfomax #DaewoongPharmaceutical #Nabota #ChinaApproval #BotulinumToxin #ProductWithdrawal #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=74601